We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
<sup>19</sup>F NMR in vivo spectroscopy reflects the effectiveness of perfusion-enhancing vascular modifiers for improving gemcitabine chemotherapy.
- Authors
Cron, Greg O.; Beghein, Nelson; Ansiaux, Réginald; Martinive, Philippe; Feron, Olivier; Gallez, Bernard
- Abstract
Nuclear magnetic resonance spectroscopy of fluorine-19 (19F NMR) has proven useful for evaluating kinetics of fluorinated chemotherapy drugs in tumors in vivo. This work investigated how three perfusion-enhancing vascular modifiers (BQ123, thalidomide, and Botulinum neurotoxin type A [BoNT-A]) would affect the chemotherapeutic efficacy of gemcitabine, a fluorinated drug widely used in human cancer treatment. Murine tumor growth experiments demonstrated that only BoNT-A showed a strong trend to enhance tumor growth inhibition by gemcitabine (1.7 days growth delay, P = 0.052, Student t-test). In accord with these results, 19F NMR experiments showed that only BoNT-A increased significantly the uptake of gemcitabine in tumors (50% increase, P = 0.0008, Student t-test). Further experiments on gemcitabine kinetics (NMR vs time) and distribution (19F MRI) confirmed the uptake-enhancing properties of BoNT-A. The results of this study demonstrate that 19F NMR can monitor modulation of the pharmacokinetics of fluorinated chemotherapy drugs in tumors. The results also show that 19F NMR data can give a strong indication of the effectiveness of perfusion-enhancing vascular modifiers for improving gemcitabine chemotherapy in murine tumors. 19F NMR is a promising tool for preclinical evaluation of such vascular modifiers and may ultimately be used in the clinic to monitor how these modifiers affect chemotherapy. Magn Reson Med, 2007. © 2007 Wiley-Liss, Inc.
- Publication
Magnetic Resonance in Medicine, 2008, Vol 59, Issue 1, p19
- ISSN
0740-3194
- Publication type
Article
- DOI
10.1002/mrm.21469